Source: Annual Congress 2003 - Markers, mediators and mechanisms of human lung injury
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Antoniou, M. Zervou, E. Tzortzaki, M. Dimadi, P. Latsi, V. Polychronopoulos, N. M. Siafakas, D. Bouros (Heraklion, Athens, Greece). Promoters and inhibitors m-RNAs expression before and after treatment with interferon gamma-1b or colchicine in idiopathic pulmonary fibrosis: preliminary results. Eur Respir J 2003; 22: Suppl. 45, 613

Member's Comments

No comment yet.

Related content which might interest you: Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: 496-504 Year: 2006 CTGF and TNFa expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis before and after treatment with azathioprine and interferon-g Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Treatment of Idiopathic pulmonary fibrosis with interferon beta - our experience in seven patients Source: Eur Respir J 2003; 22: Suppl. 45, 44s Year: 2003 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 In-vivo and in-vitro production of interferon gamma in pediatric patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 140s Year: 2002 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (5) 2002559; 10.1183/13993003.02559-2020 Year: 2021 Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study Source: Eur Respir J 2012; 39: 772-775 Year: 2012 Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1434-1445 Year: 2015 Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy Source: Eur Respir J 2016; 47: 889-897 Year: 2016 Colchicine, prednisone versus no therapy in idiopathic pulmonary fibosis Source: Eur Respir J 2006; 28: Suppl. 50, 744s Year: 2006